Skip to content
Search

Latest Stories

Pakistan's Rizwan and India's Pujara team up for Sussex

Pakistan's Rizwan and India's Pujara team up for Sussex

Mohammad Rizwan and Cheteshwar Pujara played for Sussex in the English County Championship on Thursday -- a rare example of Pakistani and Indian cricketers turning out for the same team.

India cut bilateral cricket ties with Pakistan after attacks in Mumbai in 2008 that authorities blamed on Pakistani militants and the teams now only play each other in multi-nation events.


The South Asian rivals have not faced each other in a bilateral series since Pakistan toured India in 2012/13 for a set of one-day internationals and Twenty20 matches during a brief thaw in relations.

Pakistan's stars also do not play in the Indian Premier League, the world's most high-profile Twenty20 competition, which is currently taking place in India.

But Pakistani wicketkeeper-batsman Rizwan and Indian batsman Pujara were both in the Sussex team for their four-day division two match against Derbyshire in Derby, which started on Thursday.

puj scaled Cheteshwar Pujara (Reuters/Lee Smith)

Sussex signed Pujara as a replacement for Travis Head last month after the Australian asked to be released from his contract due to increased international commitments.

The 34-year-old Indian batsman has scored 6,713 Test runs in 95 Tests at an average of nearly 44.

Rizwan, 29, averages nearly 43 in Test cricket and an eye-catching 50 in the T20 format.

Sussex head coach Ian Salisbury said: "I am extremely excited to be able to bring in players of Rizwan and Pujara’s quality into the side.

"Not only are they absolute world-class cricketers that will boost our performances on the pitch, but to have them around the boys and in the dressing room can only be a positive."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less